SPS
NKTR icon

Susquehanna Portfolio Strategies’s Nektar Therapeutics NKTR Stock Holding History

Susquehanna Portfolio Strategies’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.48M Buy
34,527
+18,470
+115% +$1.05M 0.04% 445
2025
Q4 		$679K Hold
16,057
– – 0.01% 717
2025
Q3 		$914K Buy
+16,057
New +$531K 0.01% 701

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Susquehanna Portfolio Strategies's NKTR Position: Q1 2026 in Review

Susquehanna Portfolio Strategies increased its Nektar Therapeutics (NKTR) stake by 115% in Q1 2026, buying an estimated $1.05M and bringing the position to 34,527 shares worth $2.48M. The position accounts for 0.04% of the portfolio, ranked #445.

Susquehanna Portfolio Strategies first reported a position in NKTR in Q3 2025 and has held it in 3 quarters since. 215 funds tracked by Wall St. Rank hold NKTR as of Q1 2026.

  • Susquehanna Portfolio Strategies held 34,527 shares of Nektar Therapeutics worth $2.48M as of Q1 2026.
  • Susquehanna Portfolio Strategies bought 18,470 Nektar Therapeutics shares in Q1 2026, an estimated $1.05M.
  • Nektar Therapeutics made up 0.04% of Susquehanna Portfolio Strategies's portfolio in Q1 2026, its #445 holding.
  • Susquehanna Portfolio Strategies first reported a position in Nektar Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • 215 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2026.

Based on Susquehanna Portfolio Strategies's 13F filing for Q1 2026, filed 15 May 2026.